Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/Explore/US Market Price/Stocks/SMMT
icon
icon
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Summit Therapeutics Inc (SMMT) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Summit Therapeutics (SMMT) trades at $15.61, down 4.7% over 24 hours, reflecting market volatility amid mixed earnings results. The stock shows a bullish technical signal with RSI near oversold levels at 29.91, while fundamentals reveal significant losses with a net income of -$1.08B in 2025 and negative ROE of -192.5%. Recent news highlights positive Phase III trial data for ivonescimab in cancer treatments, boosting investor optimism for future FDA approvals.
The outlook hinges on ivonescimab's regulatory success, with a consensus price target of $26.86 implying 72% upside. Risks include high cash burn, clinical trial uncertainties, and competitive pressures. Analyst sentiment is strongly bullish with 65% buy ratings, but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
Read full analysis

Key Stats

  • Market Cap
    $12.44B
  • Volume
    3,781,894
  • Sector
    Health
  • 52W High
    $26.38
  • 52W Low
    $12.43
  • Typical Hold Time
    18 Days
  • Enterprise Value
    $11.77B
  • Div Yield
    -
  • Trading Activity
    -
$15.61
52W Low: $12.43
20 Aug 2026
52W High: $26.38
21 Apr 2026

Track Summit Therapeutics Inc (SMMT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $12.43 and a high of $26.38, highlighting its annual price range. Buy and sell Summit Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Summit Therapeutics Inc

Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.

Most Recent News

Content is generated by Aura AI

Vanguard BND's 0.04% fee masks $254,720 in taxes over 20 years for $500K investors.

Investing $500,000 in Vanguard's Total Bond Market ETF (BND) incurs a tiny 0.04% fee but results in about $254,720 in federal taxes over 20 years for investors in the 32% tax bracket if held in a taxable account. The fund yields about 4.14% annually,...

Market News
5 hours ago
24/7 Wall Street
Neutral
Vanguard BND's 0.04% fee masks $254,720 in taxes over 20 years for $500K investors.

Nearly 10,000 runners from 52 countries join Chicago Half Marathon, with 45% first-timers and wide age range.

The 29th annual Life Time Chicago Half Marathon & 5K attracted nearly 10,000 participants from all 50 U.S. states and 52 countries, highlighting the event's global appeal. Nearly 45% of runners were completing their first half marathon or 5K, and ove...

Market News
5 hours ago
PRNewsWire
Bullish
news icon
Nearly 10,000 runners from 52 countries join Chicago Half Marathon, with 45% first-timers and wide age range.

Anthropic CEO to dine with Trump amid AI safety debate and government tensions

Anthropic CEO Dario Amodei is scheduled to have a dinner meeting with President Donald Trump, marking their first one-on-one encounter. The meeting comes amid contrasting views on AI safety, with Amodei advocating for cautious AI development and Trum...

Market News
5 hours ago
TechCrunch
Neutral
Anthropic CEO to dine with Trump amid AI safety debate and government tensions
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $12.44B
  • Volume
    3,781,894
  • Sector
    Health
  • 52W High
    $26.38
  • 52W Low
    $12.43
  • Typical Hold Time
    18 Days
  • Enterprise Value
    $11.77B
  • Div Yield
    -
  • Trading Activity
    -
$15.61
52W Low: $12.43
20 Aug 2026
52W High: $26.38
21 Apr 2026

Track Summit Therapeutics Inc (SMMT) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Summit Therapeutics Inc has traded between a low of $12.43 and a high of $26.38, highlighting its annual price range. Buy and sell Summit Therapeutics Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!